Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JMT106 in advanced solid tumors
NCT07275073Phase 1Recruiting
- Sponsor
- Shanghai Jinmante Biotechnology Co., Ltd.
- Start
- Sep 2025
- Primary completion
- Nov 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of JMT106 in solid tumor (advanced stage), squamous cell carcinoma of the lung (LSCC) and hepatocellular carcinoma (HCC), sponsored by Shanghai Jinmante Biotechnology Co., Ltd. Primary endpoints: Adverse Event at 2 years, Maximum Tolerated Dose at 1 year and 4 more. Started Sep 2025; status: recruiting.
02
Drugs
JMT106
03
Conditions
solid tumor (advanced stage)squamous cell carcinoma of the lung (LSCC)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07275073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07275073.